Prostate Cancer

Jean-Philippe Theurillat, MD, discusses castration and androgen receptor inhibition in prostate cancer.

Daniel W. Lin, MD, discusses the role of genomic markers in prostate cancer.

Sarki A. Abdulkadir, MD, PhD, discusses the rationale to target MYC in prostate cancer.

The addition of enzalutamide to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer improved radiographic progression-free survival, regardless of baseline prostate-specific antigen levels.

Paul C. Boutros, PhD, MBA, discusses processes that predict disease lethality in men with prostate cancer.

Brandon Mahal, MD, discusses the potential role of race with regard to molecular disparities among men with prostate cancer.

Monica L. Baskin, PhD, discusses treatment considerations in prostate cancer.

Arun Azad, PhD, discusses the significance of the PROfound trial in metastatic castration-resistant prostate cancer.

Philip W. Kantoff, MD, discusses future research efforts in prostate cancer.

Neal D. Shore, MD, FACS, discusses unmet needs in nonmetastatic castration-resistant prostate cancer.

Daniel P. Petrylak, MD, discusses future research in prostate cancer.

A novel surgical technique called the “hood technique” for robotic-assisted radical prostatectomy was shown to achieve early return of urinary continence without a negative impact on complications and cancer outcomes among men with localized prostate cancer.

Ray McDermott, discusses preventing recurrence in patients with very high-risk prostate cancer.

Maha Hussain, MD, FACP, FASCO, discusses the importance of meaningful effect in prostate cancer trials.

Neal D. Shore, MD, FACS, highlights the role of darolutamide plus androgen deprivation therapy and how it continues to demonstrate a highly favorable tolerability and safety profile in patients with nonmetastatic castration-resistant prostate cancer.

The combination of onvansertib plus abiraterone acetate and prednisone achieved disease control in patients with metastatic castration-resistant prostate cancer who had initial resistance to abiraterone.

Amir Goldkorn, MD, discusses circulating tumor cell count, a beneficial biomarker in patients with metastatic castration-sensitive prostate cancer.

Daniel P. Petrylak, MD, discusses the ever-changing prostate cancer armamentarium, as well as the role of biomarkers and new diagnostic methods in the space.

Arun Azad, PhD, discusses the design of the ​phase 3ARCHES trial in metastatic hormone-sensitive prostate cancer.

Philip W. Kantoff, MD, discusses the rationale to evaluate VERU-111 in metastatic castration-resistant prostate cancer.

Maha Hussain, MD, FACP, FASCO, discusses the need for treatment that elicits an overall survival benefit in patients with nonmetastatic castration-resistant prostate cancer.

Neal D. Shore, MD, FACS, discusses the design of the phase 3 HERO trial in patients with advanced prostate cancer.

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the design of the DASL-HiCAP trial in high-risk prostate cancer.

Maha H.A. Hussain, MD, FACP, FASCO, discusses the updated findings from the PROfound trial, its clinical significance in the treatment of patients with mCRPC paradigm, and the promise of precision medicine.

Neal D. Shore, MD, FACS, discusses the results from the phase 3 HERO trial with relugolix in men with advanced prostate cancer.